Innoviva (INVA) Shares Outstanding (2010 - 2026)
Innoviva's (INVA) quarterly Shares Outstanding (Entity) came in at $73.8 million in Q1 2026, up 17.58% YoY from $62.8 million in Q1 2025, and down 1.11% on a QoQ basis from $74.6 million in Q4 2025.
Innoviva (INVA) Shares Outstanding (2010 - 2026) Analysis & Trends
Innoviva (INVA) has 17 years of Shares Outstanding (Entity) data on file, last reported at $73.8 million in Q1 2026.
- Quarterly Shares Outstanding (Entity) rose 17.58% year-over-year to $73.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $73.8 million (up 17.58% YoY) and the FY2025 annual result came in at $74.6 million, up 19.1% from the prior year.
- Shares Outstanding (Entity) slipped to $73.8 million in Q1 2026, from $74.6 million in the prior quarter.
- In the past five years, Shares Outstanding (Entity) ranged from a high of $74.8 million in Q3 2025 to a low of $62.6 million in Q2 2024.
- A 5-year average of $66.9 million and a median of $65.2 million in 2023 frame the typical range for Shares Outstanding (Entity).
- Annual changes were most pronounced in 2022 — Shares Outstanding (Entity) slumped 31.37% — and 2025, when it rose 19.44%.
- Tracing INVA's Shares Outstanding (Entity) over 5 years: stood at $69.2 million in 2022, then dropped by 8.5% to $63.3 million in 2023, then decreased by 1.01% to $62.7 million in 2024, then climbed by 19.1% to $74.6 million in 2025, then slipped by 1.11% to $73.8 million in 2026.
- The last three Shares Outstanding (Entity) figures came in at $73.8 million (Q1 2026), $74.6 million (Q4 2025), and $74.8 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 253.70 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 102.80 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 62.19 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 210.89 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.45 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 25.05 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 445.06 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 133.61 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 217.35 Mn |
| 10 | Innoviva | 1.54 Bn | 968.79 Mn | 90.62 Mn | 73.42 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 73.42 Mn |
| Mar 31, 2026 | 74.16 Mn |
| Dec 31, 2025 | 67.40 Mn |
| Sep 30, 2025 | 69.06 Mn |
| Jun 30, 2025 | 62.87 Mn |
| Mar 31, 2025 | 62.71 Mn |
| Dec 31, 2024 | 62.73 Mn |
| Sep 30, 2024 | 62.57 Mn |
| Jun 30, 2024 | 62.53 Mn |
| Mar 31, 2024 | 63.19 Mn |
| Dec 31, 2023 | 65.44 Mn |
| Sep 30, 2023 | 64.95 Mn |
| Jun 30, 2023 | 65.34 Mn |
| Mar 31, 2023 | 67.79 Mn |
| Dec 31, 2022 | 69.64 Mn |
| Sep 30, 2022 | 69.73 Mn |
| Jun 30, 2022 | 69.64 Mn |
| Mar 31, 2022 | 69.54 Mn |
| Dec 31, 2021 | 82.06 Mn |
| Sep 30, 2021 | 69.46 Mn |